ClinVar Miner

Submissions for variant NM_000256.3(MYBPC3):c.1624+4A>T (rs397515916)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000168451 SCV000059070 pathogenic Hypertrophic cardiomyopathy 2019-09-19 criteria provided, single submitter clinical testing The c.1624+4A>T variant in MYBPC3 has been identified in >15 individuals with HCM and segregated with disease in 5 affected family members from 3 families (Ingles 2005, Marston 2009, Helms 2014, Burns 2017, Springer 2019, Cardiogenomics pers comm, LMM data). This variant also been identified in 3/224880 chromosomes by gnomAD ( This variant is located in the 5' splice region multiple studies have demonstrated that it causes skipping of exon 17, leading to the introduction of a premature stop codon (Helms 2014, Ito 2017, Springer 2019). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PS3, PS4, PM2, PP1_Moderate.
GeneDx RCV000158106 SCV000208041 pathogenic not provided 2018-07-19 criteria provided, single submitter clinical testing The c.1624+4 A>T pathogenic variant has been identified in the MYBPC3 gene. This variant has previously been reported in association with HCM (Ingles et al., 2005; Marston et al., 2009; Page et al., 2012; Nunez et al., 2013). Ingles et al. (2005) identified c.1624+4 A>T (reported as IVS18+4 A>T due to a different exon numbering convention) in one family with HCM. Marston et al. (2009) reported this variant in a 42 year-old male patient with HCM and a family history of sudden cardiac death in his mother. Nunez et al. (2013) identified c.1624+4 A>T in three individuals with HCM. Additionally, this variant has been observed in multiple unrelated individuals referred for HCM genetic testing at GeneDx. Splice prediction algorithms predict that c.1624+4 A>T destroys the splice donor site of intron 17, which is predicted to cause abnormal gene splicing. Consistent with this prediction, Helms et al. (2014) studied sarcomere transcript from septal myectomy and transplant patients and concluded that c.1624+4 A>T results in skipping of exon 17. The c.1624+4 A>T variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016).
Invitae RCV000168451 SCV000219148 pathogenic Hypertrophic cardiomyopathy 2020-09-24 criteria provided, single submitter clinical testing This sequence change falls in intron 17 of the MYBPC3 gene. It does not directly change the encoded amino acid sequence of the MYBPC3 protein, but it affects a nucleotide within the consensus splice site of the intron. This variant is present in population databases (rs397515916, ExAC 0.002%). This sequence change has been reported in the literature in several individuals affected with hypertrophic cardiomyopathy (PMID: 16199542, 19574547, 28790153, 23782526). This variant is also known in the literature as IVS18+4A>T and intron17 DS A>T+4. ClinVar contains an entry for this variant (Variation ID: 42556). Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Experimental studies have shown that this variant disrupts mRNA splicing (PMID: 25031304). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000249084 SCV000320645 pathogenic Cardiovascular phenotype 2019-03-01 criteria provided, single submitter clinical testing The c.1624+4A>T intronic pathogenic mutation results from an A to T substitution 4 nucleotides after coding exon 17 in the MYBPC3 gene. This alteration has been reported in multiple unrelated individuals with hypertrophic cardiomyopathy (HCM) and segregated with disease in three families tested by outside laboratories (Ingles J et al. J Med Genet. 2005;42(10):e59; Marston S et al. Circ Res. 2009;105(3):219-22; Núñez L et al. Circ J. 2013;77(9):2358-65; Burns C et al. Circ Cardiovasc Genet. 2017;10(4); LMM personal communication). Skipping of exon 17, which is predicted to lead to a frameshift, was detected on analysis of cardiac tissue from an affected carrier, and RNA analysis in blood samples from carriers identified by another group also confirmed skipping of exon 17 (Helms AS et al. Circ Cardiovasc Genet. 2014;7(4):434-43; Singer ES et al. Circ Genom Precis Med. 2019;12(1):e002368). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000211799 SCV000917817 pathogenic Primary familial hypertrophic cardiomyopathy 2018-01-02 criteria provided, single submitter clinical testing Variant summary: The MYBPC3 c.1624+4A>T variant involves the alteration of a conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict the weakening or loss of a cannonical splice donor site, which has been confirmed by functional studies which show the variant to lead to exon 17 skipping and premature termination (Helms_2014). This variant was found in 3/223428 control chromosomes at a frequency of 0.0000134, which does not exceed the estimated maximal expected allele frequency of a pathogenic MYBPC3 variant (0.0010005).The variant has been reported in numerous affected individuals in the literature (Ingles_2005, Marston_2009, Page_2012, Nunez_2013, Helms_2016), and has been reported by clinical labs to be detected in individuals being tested for HCM (ClinVar). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Blueprint Genetics RCV000158106 SCV000927910 pathogenic not provided 2018-09-03 criteria provided, single submitter clinical testing
Color Health, Inc RCV001180068 SCV001344922 pathogenic Cardiomyopathy 2020-02-25 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000158106 SCV001713566 pathogenic not provided 2019-09-16 criteria provided, single submitter clinical testing PS3, PS4_moderate PM2, PP1, PP3
Stanford Center for Inherited Cardiovascular Disease, Stanford University RCV000158106 SCV000280218 likely pathogenic not provided 2015-06-19 no assertion criteria provided clinical testing Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. MYBPC3 IVS17+4A>T Based on the data reviewed below we consider it likely disease causing. The variant has been seen in at least 10 and as many as 13 unrelated cases of HCM. There is no segregation data. Ingles et al (2005) reported the variant 1 of 80 individuals with HCM in their Australian cohort (variant referred to as IVS18+4A>T). Kaski et al (2009) reported the variant in 1 of 79 pediatric cases of HCM from their British cohort (variant referred to as IVS18+4A>T). The same group reported what appears to be the same variant (referred to as intron17 DS A>T+4) in a 42yo male with HCM and a family history of sudden death and HCM (Marston et al 2009). They note they studied two additional patients with this variant but do not provide clinical details. The same group later reported IVS17+4>T in three affected individuals (Page et al 2012), which presumably overlap with the cases studied in Marston et al (2009). It is unclear whether these overlap with the pediatric case initially reported by this group (Kaski et al 2009) or whether these three individuals are related to one another. Maron et al (2012) reported the variant in a patient labeled as "genotype positive-phenotype negative" who had myocardial crypts on MRI. Two different splicing algorithms predict the variant to alter splicing. Thus it is expected to lead to no protein product due to nonsense mediated decay or to a truncated protein product. Marston et al (2009) studied myectomy samples from three individuals with this variant. They did not detect a truncated protein product but they did see in all three cases that the amount of protein was significantly decreased compared to heart tissue samples from hearts without HCM (donor hearts) and HCM patients without MYBPC3 variants. Splicing and other protein-truncating variants in MYBPC3 are a frequent cause of HCM (Erdmann et al. 2001 & 2003; Stenson et al 2003; Harvard Sarcomere Protein Gene Mutation Database). MYBPC3 splice variants reported in association with HCM include IVS2-1G>A, IVS6-2A>C IVS7+1G>A, IVS8+1G>A, IVS12-2A>G, IVS14-2A>G, IVS16-1G>A, IVS22+1G>A, IVS24+1G>A, IVS28+1G>A, IVS32+1G>A, and IVS33+1G>A (Harvard Sarcomere Protein Gene Mutation Database). In total the variant has not been seen in ~6950 published controls and individuals from publicly available population datasets. The variant is not listed in the NHLBI Exome Sequencing Project dataset, which currently includes variant calls on ~6200 Caucasian and African American individuals (as of February 12th, 2013). The variant is not listed in dbSNP or 1000 genomes. The variant was not observed in the following published and laboratory control samples: 200 presumed healthy individuals analyzed at GeneDx, over 400 presumed healthy individuals analyzed at Transgenomic, 150 healthy adults studied by Ingles et al (2005).
GenomeConnect, ClinGen RCV000158106 SCV000784698 not provided not provided no assertion provided phenotyping only GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.